Evidence map›Paper›PMID 37753087›Full record

ArticleFrontiers in immunology2023

Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice.

Dominik Pflumm, Alina Seidel, Fabrice Klein, Rüdiger Groß, Lea Krutzke, Stefan Kochanek, Joris Kroschel, Jan Münch, Katja Stifter, Reinhold Schirmbeck

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dominik PflummDepartment of Internal Medicine I, University Hospital of Ulm, Ulm, Germany.
Alina SeidelInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Fabrice KleinDepartment of Gene Therapy, University Hospital of Ulm, Ulm, Germany.
Rüdiger GroßInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Lea KrutzkeDepartment of Gene Therapy, University Hospital of Ulm, Ulm, Germany.
Stefan KochanekDepartment of Gene Therapy, University Hospital of Ulm, Ulm, Germany.
Joris KroschelInstitute of Clinical Chemistry, Ulm University Medical Center, Ulm, Germany.
Jan MünchInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Katja StifterDepartment of Internal Medicine I, University Hospital of Ulm, Ulm, Germany.
Reinhold SchirmbeckDepartment of Internal Medicine I, University Hospital of Ulm, Ulm, Germany.
University Hospital Ulm · DEUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multitude of alterations in the old immune system impair its functional integrity. Closely related, older individuals show, for example, a reduced responsiveness to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines. However, systematic strategies to specifically improve the efficacy of vaccines in the old are missing or limited to simple approaches like increasing the antigen concentration or injection frequencies. We here asked whether the intrinsic, trimeric structure of the SARS-CoV-2 spike (S) antigen and/or a DNA- or protein-based antigen delivery platform affects priming of functional antibody responses particularly in old mice. The used S-antigens were primarily defined by the presence/absence of the membrane-anchoring TM domain and the closely interlinked formation/non-formation of a trimeric structure of the receptor binding domain (S-RBD). Among others, we generated vectors expressing prefusion-stabilized, cell-associated (TM

Indexed as

Blood Group AntigensCOVID-19Vaccines, DNAAnimalsAntibodies, NeutralizingImmunizationMiceSARS-CoV-2Antibodies, NeutralizingBlood Group AntigensVaccines, DNAantibody responseantigen conformationold miceSARS-CoV-2spike antigenvaccination regimens

Identifiers

PMID37753087
PMCPMC10518615
OpenAlexW4386617243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.